Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Radiopharm Theranostics Limited ( (AU:RAD) ) has shared an announcement.
Radiopharm Theranostics Limited announced a webinar series featuring key opinion leaders to discuss the use of radiopharmaceutical therapies in oncology, particularly for prostate cancer. This initiative highlights the company’s focus on innovative cancer treatments, including their B7-H3-targeted radiopharmaceutical therapy developed in partnership with MD Anderson Cancer Center, and the KLK3-targeting RAD402 therapy for prostate cancer, which is undergoing a Phase I trial.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a company specializing in the development of radiopharmaceutical products for diagnostic and therapeutic purposes, with a focus on oncology and prostate cancer treatment.
Average Trading Volume: 2,784,913
Technical Sentiment Signal: Sell
Current Market Cap: A$61.49M
For detailed information about RAD stock, go to TipRanks’ Stock Analysis page.